CEO presentation - one of the best I have seen., page-56

Hi PlatiumStandard,

Here is why I see bigger potential in ADAPT.
ADAPT tissue is the main differentiating factor why our TAVR product having major clinical advantages over the incumbents. The majors can build a better delivery system than ours with their strong research talents, but without ADADT, they only have an inferior products to market.

When asked if there were any ways to increase the longevity of the existing valves currently on the market, Wayne said some could try to repair the deteriorating valve with tissue like ADAPT or replace the valve altogether. Wayne also said the results of the first in human trial using DUrAVR value via SAVR has delivered the unexpected level hemodynamics benefits. It sound to me that ADAPT could well be used in much more innovative products which are not even in the market.

That’s how I see the true potential of ADAPT in enabling medical technology innovations.

DYOR!